Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000155445 | SCV000205136 | uncertain significance | not specified | 2013-04-05 | criteria provided, single submitter | clinical testing | The Arg1569Cys variant in COL11A2 has not been reported in affected individuals or in large population studies. Computational analyses (biochemical amino acid p roperties, conservation, AlignGVGD, PolyPhen2, and SIFT) suggest that the Arg156 9Cys variant may impact the protein, though this information is not predictive e nough to determine pathogenicity. In summary, the clinical significance of this variant cannot be determined with certainty. |
Gene |
RCV000766673 | SCV000581864 | uncertain significance | not provided | 2024-04-15 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV000766673 | SCV001506690 | benign | not provided | 2023-12-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002516131 | SCV003540116 | uncertain significance | Inborn genetic diseases | 2022-08-30 | criteria provided, single submitter | clinical testing | The c.4705C>T (p.R1569C) alteration is located in exon 63 (coding exon 63) of the COL11A2 gene. This alteration results from a C to T substitution at nucleotide position 4705, causing the arginine (R) at amino acid position 1569 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |